In an updated profile, MIT biomedical engineer Sangeeta Bhatia discussed how her Bio-MEMS and liver research have evolved over the past 13 years, including work tied to infectious disease and advances toward functional liver-cell engineering. Bhatia highlighted foundational liver findings, including conditions hepatocytes need to survive outside the body, and contrasted approaches using induced pluripotent stem cell (iPSC)–derived liver cells. A key theme was that iPSC-derived liver cells transplanted into mice failed to fully function, stalling before maturity. Bhatia argued that the liver’s regenerative biology offers a route to mature cell division without relying on stem-cell states, linking the physiology of regeneration to translational engineering objectives. The profile also noted that her lab reported the first transcriptome of a dormant human malaria strain that can reactivate, derived from work in Southeast Asia. It further described translation efforts involving vascular bioengineer Christopher Chen at Boston University. While the excerpt reads as an interview-style update rather than a discrete trial announcement, it underscores ongoing translational priorities in organ engineering—particularly creating liver-compatible cell products that can actually mature and function in vivo.